MRVI in the 13F filings
Maravai Lifesciences HLDGS I · CUSIP 56600D107
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 5 Aug 2026
- Managers listing it
- 25
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 1 listed it in both
- Shares listed
- 28,515,659
- combined, among listed positions
- Reported value
- $177m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 19 buyers (opened or added shares) and 7 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +8,714,690.
Managers listing MRVI in Q2 2026
25 of 25 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 6,508,220 shares now+4,858,730
- Arrowstreet Capital LPnew position · 1,513,606 shares now+1,513,606
- Tudor Investment Corpexisting position · 1,849,079 shares now+1,452,164
- First Eagle Investment Management LLCexisting position · 3,671,287 shares now+1,146,951
- Verition Fund Management LLCnew position · 777,738 shares now+777,738
Reductions
- Jane Street Group LLCexisting position · 142,590 shares now-1,493,555
- Point72 Asset Management LPexisting position · 2,005,579 shares now-1,199,917
- Marshall Wace LLPexisting position · 1,471,477 shares now-609,857
- Susquehanna International Group LLPexisting position · 57,593 shares now-129,046
- AllianceBernstein LPexisting position · 140,401 shares now-18,700
New positions and exits
New (8)
Exited (1)
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 11 | $410m | n.a. | n.a. |
| Q1 2021 | 4 | $230m | n.a. | n.a. |
| Q2 2021 | 8 | $819m | n.a. | n.a. |
| Q3 2021 | 10 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 6 | $900m | n.a. | n.a. |
| Q1 2022 | 4 | $342m | n.a. | n.a. |
| Q2 2022 | 4 | $447m | n.a. | n.a. |
| Q3 2022 | 7 | $527m | n.a. | n.a. |
| Q4 2022 | 8 | $360m | n.a. | n.a. |
| Q1 2023 | 8 | $291m | n.a. | n.a. |
| Q2 2023 | 7 | $234m | n.a. | n.a. |
| Q3 2023 | 6 | $155m | n.a. | n.a. |
| Q4 2023 | 3 | $73m | 2 | 1 |
| Q1 2024 | 5 | $110m | 2 | 3 |
| Q2 2024 | 6 | $91m | 4 | 2 |
| Q3 2024 | 1 | $34m | 1 | 1 |
| Q4 2024 | 1 | $251k | n.a. | n.a. |
| Q3 2025 | 1 | $1.3m | 1 | 0 |
| Q4 2025 | 1 | $5.8m | 13 | 9 |
| Q1 2026 | 1 | $7.1m | 13 | 7 |
| Q2 2026 | 2 | $24m | 19 | 7 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MRVI and LLY →MRVI and JNJ →MRVI and VRTX →Choose a stock to compare with MRVI →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MRVI, latest filings →Back to the 13F Explorer →